<DOC>
	<DOCNO>NCT01095640</DOCNO>
	<brief_summary>Marketed Galderma Laboratories , L.P. , Differin® ( adapalene 0.3 % topical gel ) safe effective topical therapy use treatment acne vulgaris . Actavis Mid-Atlantic LLC develop generic formulation adapalene 0.3 % topical gel current study design evaluate safety efficacy formulation .</brief_summary>
	<brief_title>Study Comparing 0.3 % Adapalene Topical Gel Differin® 0.3 % Adapalene Topical Gel</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Adapalene</mesh_term>
	<criteria>1 . Male female patient must 12 year old old . 2 . Patients 18 year age old must provide IRB approve write informed consent . Patients age 12 17 year age must provide IRB approve write assent ; write assent must accompany IRB approve write informed consent patient 's legally acceptable representative ( i.e. , parent guardian ) . In addition , patient legally acceptable representative ( i.e. , parent guardian ) must sign HIPAA authorization , applicable 3 . Patients must definite clinical diagnosis acne vulgaris mild moderate severity ( Grade 2 Grade 3 IGE ) . 4 . Patients must minimum 20 maximum 60 facial inflammatory lesion baseline . Patients must also minimum 20 maximum 75 facial comedo baseline . Patients may one ( 1 ) nodulocystic lesion baseline . For purpose study treatment evaluation , lesion limit facial treatment area . Lesions involve eye , angle nose ( i.e. , line around nostril nostril ) scalp exclude count . Patients may acne lesion area body ( e.g. , back ) . 5 . Female patient childbearing potential must use must agree continue practice abstinence use accept method birth control , 30 day prior study entry 30 day last administration study drug . All female patient consider childbearing potential unless surgically sterilize postmenopausal least 1 year . Abstinence acceptable method birth control . Alternatively , follow method birth control acceptable : oral contraceptive , contraceptive patches/implants ( e.g. , Norplant® ) DepoProvera® , double barrier method ( e.g. , condom spermicide ) IUD . Female patient must negative urine pregnancy test baseline . 6 . All male patient must agree use accept method birth control partner , day first dose administration 30 day last administration study drug . Abstinence acceptable method birth control . Alternatively , follow method birth control acceptable : oral contraceptive , contraceptive patches/implants ( e.g. , Norplant® ) , DepoProvera® , double barrier method ( e.g. , condom spermicide ) IUD . 7 . Patients must willing able understand comply requirement protocol , include attendance require study visit . 8 . Patients must willing refrain use treatment acne vulgaris , investigational product , acne present face . Patients may use topical acne treatment significant measurable systemic absorption treatment acne back , shoulder chest ( e.g. , benzoyl peroxide , salicylic acid ) . 9 . Patients must good health free clinically significant disease , include limited , condition may interfere evaluation acne vulgaris . Such condition include , limited following : rosacea ; seborrheic dermatitis ; perioral dermatitis ; corticosteroidinduced acne ; carcinoid syndrome ; mastocytosis ; acneiform eruption cause makeup , medication , facial psoriasis facial eczema . 10 . Patients use makeup must use brands/types makeup minimum period 14 day prior study entry must agree change makeup brand/type frequency use throughout study . 1 . Female patient pregnant , nurse plan become pregnant study participation ( Visit 1 Visit 5 Early Discontinuation Visit ) exclude study participation . 2 . Patients know hypersensitivity adapalene excipients exclude study participation . 3 . Patients acne congoblata , acne fulimans , secondary acne ( e.g. , chloracne drug induce acne ) exclude participation . 4 . Patients treat systemic antibiotic systemic antiacne drug within 30 day prior baseline exclude study participation . 5 . Patients treated prescription and/or overthecounter topical medication treatment acne vulgaris include antibiotic , topical corticosteroid topical antiinflammatory medication face within 14 day prior baseline exclude study participation . 6 . Patients currently take treat corticosteroid ( include intranasal inhaled corticosteroid ) within 30 day prior baseline exclude study participation . 7 . Patients start hormonal therapy change dosage hormonal therapy within 30 day prior baseline exclude study participation . The dosage frequency use hormonal therapy start great 30 day prior baseline must remain unchanged throughout study ( Visit 1 Visit 5 Early Discontinuation Visit ) . Hormonal treatment include , limited , estrogenic progestational agent birth control pill . 8 . Patients receive oral retinoids ( e.g. , isotretinoin ) within 180 day prior study entry apply topical retinoids ( e.g. , tretinoin , tazarotene , adapalene ) face within 30 day prior baseline exclude study participation . 9 . Patients receive radiation therapy and/or antineoplastic agent within 90 day prior baseline exclude study participation . 10 . Patients unstable medical disorder clinically significant lifethreatening disease exclude study participation . 11 . Patients ongoing malignancy require systemic treatment exclude study participation . In addition , patient malignancy skin facial area exclude study participation . 12 . Patients facial hair exclude study participation . Unacceptable facial hair include , limited , beard long sideburn . A welltrimmed mustache acceptable . Patients perform wax epilation face within 14 day prior baseline also exclude study participation . 13 . Patients engage activity involve excessive prolonged exposure sunlight weather extreme , wind cold , exclude study participation . 14 . Patients consume excessive amount alcohol ( great two drink per day ) use drug abuse ( include , limited , cannabinoids , cocaine barbiturate ) judge history exclude study participation . 15 . Patients participate investigational drug study ( i.e. , patient treat investigational drug ) within 30 day prior baseline exclude study participation . Patients participate nontreatment study observational study registry study consider inclusion . 16 . Patients previously enrol study exclude study participation . 17 . Patients laser therapy , electrodessication phototherapy ( e.g. , ClearLight® ) facial area within 180 day prior study entry exclude participation . 18 . Patients cosmetic procedure ( e.g. , facial ) may affect efficacy safety profile investigational product within 14 day prior study entry exclude participation . 19 . Patients currently recently bacterial folliculitis exclude participation . 20 . Patients baseline local irritation score 3 ( severe , marked/intense ) score use Local Irritation Scale ( Section 5.2 ) exclude participation .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>acne</keyword>
	<keyword>adapalene</keyword>
	<keyword>Differin</keyword>
</DOC>